GlassScriptPhysician profile
Anup Shah
NPI 1285088823
$1,035.59
in general payments reported to CMS, 2019-2025
14 companies · $224 in 2025
The $224 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $217 · 2023: $315 · 2024: $280 · 2025: $224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $819.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $818.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $220.48 | 2022-2025 | Skyrizi |
| Janssen Biotech, INC. | $187.75 | 2023-2025 | Stelara, Simponi Aria, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $170.31 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Cumberland Pharmaceuticals, INC. | $94.21 | 2022 | |
| Pfizer INC. | $63.31 | 2023-2024 | |
| Qol Medical, LLC | $61.88 | 2022-2023 | Sucraid |
| Janssen Scientific Affairs, LLC | $58.19 | 2023 | Stelara |
| Phathom Pharmaceuticals, INC. | $46.33 | 2024-2025 | Voquezna |
| Celgene Corporation | $45.43 | 2023-2024 | Zeposia |
| Lilly USA, LLC | $20.58 | 2025 | Omvoh |
| Novo Nordisk INC | $17.97 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $17.68 | 2023 | Dupixent |
| Merck Sharp & Dohme LLC | $17.00 | 2024 | Bridion |
| Ferring Pharmaceuticals INC. | $14.47 | 2023 | Cimzia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anup Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.